Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
S-8 - Celularity Inc (0001752828) (Filer)
424B3 - Celularity Inc (0001752828) (Filer)
8-K - Celularity Inc (0001752828) (Filer)
NEW YORK, May 14, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ:GXGX), a publicly-traded special purpose acquisition company, announced today that its stockholders have voted to approve an amendment to GX's amended and restated certificate of incorporation to extend the date by which GX must effectuate its initial business combination from May 23, 2021 to July 31, 2021. As previously disclosed, on January 8, 2021, GX entered into a Merger Agreement and Plan of Reorganization (the "Merger Agreement") with Celularity Inc. ("Celularity"), Alpha First Merger Sub, Inc. and Alpha Second Merger Sub, LLC. Upon the terms and subject to the conditions of the Merger Agreement, Celularity wi
NEW YORK, May 10, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ:GXGX), a publicly-traded special purpose acquisition company, today reaffirmed its intention to support the proposal to amend GX's amended and restated certificate of incorporation to extend the date by which GX must complete its initial business combination from May 23, 2021 to July 31, 2021 (the "Extension" and such later date, the "Extended Date"). This proposal will be voted on by stockholders at the upcoming special meeting of stockholders on May 14, 2021. The Extension will allow GX until the Extended Date to complete its initial business combination. In order to support this proposal, GX has agreed that, if the
Celularity to leverage Palantir's next generation software and computational capabilities with their deep cellular data set to accelerate research and development activities Partnership includes equity investment by Palantir in Celularity Investment, combined with previously announced PIPE investment, brings over$100 million in new funding to Celularity FLORHAM PARK, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. ("Celularity"), a clinical-stage biotechnology company leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and Palantir Technologies Inc. (NYSE:PLTR), a software company t
BTIG Research initiated coverage of GX Acquisition Corp with a rating of Buy and set a new price target of $16.00
3 - Celularity Inc (0001752828) (Issuer)
SC 13G - Celularity Inc (0001752828) (Subject)
SC 13D - Celularity Inc (0001752828) (Subject)
SC 13G - Celularity Inc (0001752828) (Subject)